Andrew C. Huang
Research Subjects
Andrew C. Huang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bing Zhu
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
1 shared publication - Jianmin Fang
School of Life Science and Technology, Tongji University, 1239 Siping Road, Shanghai 200092, PR China; Biomedical Research Center, Tongji University Suzhou Institute, Building 2,198 Jinfeng Road, Wuzhong District, Suzhou, Jiangsu 215101, PR China
1 shared publication - Jing Huang
Vascular Biology Program, Boston Children’s Hospital, Boston, MA 02115, USA
1 shared publication Lingxiao Jiang
School of Life Science and Technology, Tongji University, Shanghai 200092, China
1 shared publication- Marsha A. Moses
Vascular Biology Program Boston Children's Hospital Boston MA 02115 USA
1 shared publication - Peng Guo
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 5 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (18) , eabq7866
A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo
Triple-negative breast cancer (TNBC) remains the most lethal form of breast cancer, and effective targeted therapeutics are in urgent need to improve the poor prognosis of TNBC patients. Here, we report the development of a rationally designed antibody drug conjugate (ADC) for the treatment of late-stage and refractory TNBC. We determined that intercellular adhesion molecule-1 (ICAM1), a cell surface receptor overexpressed in TNBC, efficiently facilitates receptor-mediated antibody internalization. We next constructed a panel of four ICAM1 ADCs using different chemical linkers and warheads and compared their in vitro and in vivo efficacies against multiple human TNBC cell lines and a series of standard, late-stage, and refractory TNBC in vivo models. An ICAM1 antibody conjugated with monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker was identified as the optimal ADC formulation owing to its outstanding efficacy and safety, representing an effective ADC candidate for TNBC therapy.
- 5 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (18) , eabq7866
Open AccessA rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo
Triple-negative breast cancer (TNBC) remains the most lethal form of breast cancer, and effective targeted therapeutics are in urgent need to improve the poor prognosis of TNBC patients. Here, we report the development of a rationally designed antibody drug conjugate (ADC) for the treatment of late-stage and refractory TNBC. We determined that intercellular adhesion molecule-1 (ICAM1), a cell surface receptor overexpressed in TNBC, efficiently facilitates receptor-mediated antibody internalization. We next constructed a panel of four ICAM1 ADCs using different chemical linkers and warheads and compared their in vitro and in vivo efficacies against multiple human TNBC cell lines and a series of standard, late-stage, and refractory TNBC in vivo models. An ICAM1 antibody conjugated with monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker was identified as the optimal ADC formulation owing to its outstanding efficacy and safety, representing an effective ADC candidate for TNBC therapy.